Bavarian Nordic A/S 2012 SR
The report highlights Bavarian Nordic's transition from a research-based company to a fully integrated vaccine production entity. In 2012, the company significantly improved its environmental efficiency, nearly doubling production output while reducing total CO2 emissions by 4% and relative emissions per dose by 27%. Key focus areas included the development of the PROSTVAC cancer vaccine and IMVAMUNE smallpox vaccine. The company also implemented corporate values across its global workforce of 461 employees and prepared for the launch of an ethical hotline in 2013.
Company: Bavarian Nordic A/S
Sector: Manufacturing
Country: Denmark
Year: 2012
Type: SR
Pages: 24
Back to company
Bavarian Nordic A/S
CSR Report
The report highlights Bavarian Nordic's transition from a research-based company to a fully integrated vaccine production entity. In 2012, the company significantly improved its environmental efficiency, nearly doubling production output while reducing total CO2 emissions by 4% and relative emissions per dose by 27%. Key focus areas included the development of the PROSTVAC cancer vaccine and IMVAMUNE smallpox vaccine. The company also implemented corporate values across its global workforce of 461 employees and prepared for the launch of an ethical hotline in 2013.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2012
Reporting Period
Jan 1, 2012 - Dec 31, 2012
Fiscal Year
2012
Published
Mar 12, 2013
Type
Sustainability Report
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
Assurance
Assurance Provider
Assurance Standard
Other Standards
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Water Consumption
Total Waste
Employees